Changeflow GovPing Pharma & Drug Safety Compositions and Methods Involving Transforming...
Routine Notice Added Final

Compositions and Methods Involving Transforming Extracellular Vesicles

Favicon for changeflow.com ChangeBridge: EPO Bulletin - Pharma (A61K)
Published March 25th, 2026
Detected April 2nd, 2026
Email

Summary

The European Patent Office published patent EP3826603A1 granted to Mayo Foundation for Medical Education and Research. The patent covers compositions and methods involving transforming extracellular vesicles, with designated states across EU member states and other European jurisdictions.

What changed

EPO granted patent EP3826603A1 to Mayo Foundation for Medical Education and Research on March 25, 2026. The patent relates to compositions and methods involving transforming extracellular vesicles, classified under multiple IPC codes including A61K 8/11, A61K 35/16, and A61K 9/51. The designated states cover all EU member states plus Switzerland, Norway, and other European Patent Convention members.

This patent grant establishes exclusive intellectual property rights for Mayo Foundation in the specified jurisdictions. Competitors developing similar extracellular vesicle technologies should review potential infringement implications. Healthcare and pharmaceutical companies utilizing extracellular vesicle compositions should conduct freedom-to-operate analyses to assess licensing requirements.

What to do next

  1. Review patent claims for potential overlap with existing or planned products involving extracellular vesicles
  2. Conduct freedom-to-operate analysis if developing similar technologies
  3. Consider licensing negotiations with Mayo Foundation if relevant compositions are within patent scope

Source document (simplified)

← EPO Patent Bulletin

COMPOSITIONS AND METHODS INVOLVING TRANSFORMING EXTRACELLULAR VESICLES

Publication EP3826603A1 Kind: A1 Mar 25, 2026

Applicants

Mayo Foundation for Medical Education and Research

Inventors

SABBAH, Michael, BEHFAR, Atta, LIVIA, Christopher, PETERSON, Timothy

IPC Classifications

A61K 8/11 20060101AFI20220401BHEP A61K 8/14 20060101ALI20220401BHEP A61K 8/98 20060101ALI20220401BHEP A61K 31/7088 20060101ALI20220401BHEP A61K 31/713 20060101ALI20220401BHEP A61K 38/00 20060101ALI20220401BHEP A61K 39/00 20060101ALI20220401BHEP A61K 9/127 20060101ALI20220401BHEP A61K 9/51 20060101ALI20220401BHEP A61K 35/16 20150101ALI20220401BHEP

Designated States

AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LI, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR

View original document →

Named provisions

Compositions and Methods Involving Transforming Extracellular Vesicles

Source

Analysis generated by AI. Source diff and links are from the original.

Classification

Agency
EPO
Published
March 25th, 2026
Instrument
Notice
Legal weight
Binding
Stage
Final
Change scope
Minor
Document ID
EP3826603A1

Who this affects

Applies to
Healthcare providers Pharmaceutical companies Medical device makers
Industry sector
3254 Pharmaceutical Manufacturing 3345 Medical Device Manufacturing 6211 Healthcare Providers
Activity scope
Patent Licensing Biotechnology Development Pharmaceutical Manufacturing
Geographic scope
European Union EU

Taxonomy

Primary area
Intellectual Property
Operational domain
Legal
Topics
Healthcare Pharmaceuticals

Get Pharma & Drug Safety alerts

Weekly digest. AI-summarized, no noise.

Free. Unsubscribe anytime.

Get alerts for this source

We'll email you when ChangeBridge: EPO Bulletin - Pharma (A61K) publishes new changes.

Optional. Personalizes your daily digest.

Free. Unsubscribe anytime.